A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients with Advanced Cancers

PrintE-mailPDF
Title A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of CBLB502 in Patients with Advanced Cancers
Contact FS
Principal Investigator Alex Adjei, MD PhD
Study Number 196111
Phase1
Summary The purpose of the study is to find the tolerable dose of an investigational drug CBLB502 that can be given to patients with cancer without causing severe side effects.  Also, to find out the effectiveness of CBLB502 in advanced cancers.
Eligibility
  • Adult patients (18 years and older) with a diagnosis of advanced solid tumors
  • Patients must have adequate organ function
  • No previous anti-cancer chemotherapy, immunotherapy or investigational agents <= 3 weeks prior to the first day of study defined treatment
  • Patients must not be pregnant or breastfeeding
For more information about the clinical study go to Clinicaltrial.Gov

Cancer Talk Blog
Understanding Brain Tumors: The Basics
May is National Brain Tumor Awareness Month. To help you begin to understand this complex group of tumors, we have compiled some of the key facts, statistics and information below. Learn about the Neuro-oncology Center at Roswell Park or consult the links and sources below for more information. Brain Tumor Facts and Figures
Read more

Ask A Question

Do you have a cancer question you’d like RPCI cancer experts to address? Submit a topic for consideration.

New to RSS? Learn More

close